UCB Receives EC Approval For Cimzia In Combination With MTX
The European Commission (EC) has approved UCB’s Cimzia, in combination with MTX, for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.